{
  "id": 17095159,
  "title": "Freedom Broker raises Biogen stock price target on strong results",
  "url": "https://urgent.news/2026/10/29/freedom-broker-raises-biogen-stock-price-target-on-strong-results",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T17:12:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/freedom-broker-raises-biogen-stock-price-target-on-strong-results-93CH-4984814"
  },
  "original_language": "en",
  "account": "Freedom Broker upgraded its price target for Biogen Inc. shares to $275 from $255, while keeping a Buy rating on the stock. The company's shares are currently priced at $252.42, close to their 52-week high of $258.78. Freedom Broker highlighted strong quarterly performance and product-specific one-time benefits as key drivers behind the revised target. However, they anticipate headwinds in the fourth quarter of 2026 due to synergies from the Apellis acquisition. The firm emphasized Biogen's conservative earnings guidance, noting that the earnings beat was not solely a result of one-time factors. Instead, they cited the resilience of key products and the positive impact of Apellis' contribution. Following Biogen's remarkable 65% return over the past year, analysts have revised their earnings upwards. InvestingPro suggests the stock may be undervalued, based on its Fair Value analysis, and 9 analysts have raised their earnings forecasts for the upcoming period. Biogen's third-quarter 2026 results exceeded expectations, with adjusted earnings of $2.62 per share and revenue of $2.8 billion. The company's performance in the Rare Diseases and Specialized Immunology segments has been particularly noteworthy. Argus upgraded Biogen's rating to Buy, while BofA Securities raised its target price to $257. Baird also increased its price target to $290, highlighting the strong demand for Biogen's rare disease treatments and the upcoming launch of new products like Leqembi IQLIK.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}